Dysfunkcja seksualna kobiet

Dysfunkcja seksualna kobiet
Epidemiologia

Dysfunkcja seksualna kobiet (FSD) stanowi istotny problem zdrowia publicznego o wieloczynnikowej etiologii, obejmującej aspekty anatomiczne, fizjologiczne, medyczne, psychologiczne i społeczne. Epidemiologiczne dane wskazują, że FSD dotyka około 40-50% kobiet w wieku reprodukcyjnym, z około 12% doświadczających istotnego cierpienia związanego z tymi zaburzeniami. Według klasyfikacji DSM-5, FSD dzieli się na trzy główne kategorie: zaburzenia pożądania i podniecenia, zaburzenia orgazmu oraz zaburzenia bólowe narządów płciowych i penetracji, z objawami utrzymującymi się co najmniej 6 miesięcy i występującymi w 75-100% kontaktów seksualnych. Częstość występowania poszczególnych typów dysfunkcji w badaniach populacyjnych wynosi: zaburzenia pożądania 22-45,3%, podniecenia 14-37,5%, problemy z lubrykacją 21-41,2%, zaburzenia orgazmu 10-42%, dyspareunia/ból 7-42,5%, a waginizm 4-6%. Szczególnie wysokie wskaźniki FSD obserwuje się u kobiet w okresie menopauzy (około 52,4%) oraz u kobiet w ciąży (50-80%) i po porodzie (83%).

Epidemiologia dysfunkcji seksualnej kobiet

Globalne rozpowszechnienie dysfunkcji seksualnej kobiet
Typy dysfunkcji seksualnych i ich rozpowszechnienie
Dysfunkcje seksualne w różnych grupach wiekowych
Czynniki ryzyka dysfunkcji seksualnej kobiet
Dysfunkcje seksualne związane ze schorzeniami medycznymi i psychicznymi
Dysfunkcje seksualne w okresie ciąży i menopauzy
Dysfunkcje seksualne a poziom nierówności płci
Poszukiwanie pomocy medycznej w przypadku dysfunkcji seksualnych

Podsumowanie danych epidemiologicznych

Kolejne rozdziały

Epidemiologia dysfunkcji seksualnej kobiet

Dysfunkcja seksualna kobiet (ang. Female Sexual Dysfunction, FSD) stanowi istotny problem zdrowia publicznego o charakterze wieloczynnikowym, obejmującym aspekty anatomiczne, fizjologiczne, medyczne, psychologiczne i społeczne. Podobnie jak zaburzenia erekcji u mężczyzn, FSD występuje często, a jednocześnie pozostaje niedostatecznie diagnozowana i leczona.¹ Dokładne dane epidemiologiczne na temat rozpowszechnienia dysfunkcji seksualnych kobiet są niezbędne dla zrozumienia obciążenia tą chorobą w populacji oraz określenia czynników ryzyka umożliwiających działania profilaktyczne.²

Globalne rozpowszechnienie dysfunkcji seksualnej kobiet

Badania epidemiologiczne wskazują, że dysfunkcje seksualne dotyczą około 40% kobiet na całym świecie, przy czym około 12% (jedna na osiem kobiet) doświadcza dysfunkcji seksualnej związanej z osobistym lub interpersonalnym cierpieniem.³⁴ Metaanaliza z 2016 roku, obejmująca 215 740 kobiet w wieku reprodukcyjnym na całym świecie, wykazała, że 41% kobiet zgłasza jakąś formę dysfunkcji seksualnej.⁵ Dane te potwierdzają również wyniki najnowszej systematycznej analizy i metaanalizy, które wskazują, że częstość występowania FSD u kobiet w wieku przedmenopauzalnym szacuje się na 40,9% (95% CI = 37,1-44,7).⁶

National Health and Social Life Survey (NHSLS) przeprowadzone w Stanach Zjednoczonych wykazało wysoką ogólną częstość występowania FSD (43%) wśród amerykańskich kobiet w wieku 18-59 lat.⁷⁸ W badaniach populacyjnych szacunki występowania dysfunkcji seksualnych wahają się od 22% do 43%.⁹

Interesujące są również dane z badania PRESIDE (Prevalence of Female Sexual Problems Associated With Distress and Determinants of Treatment Seeking), które wykazało, że chociaż skorygowany względem wieku współczynnik częstości występowania dysfunkcji seksualnej u amerykańskich kobiet wynosi 44%, to cierpienie związane z dysfunkcją seksualną zgłasza 12% badanych.¹⁰

Typy dysfunkcji seksualnych i ich rozpowszechnienie

Według klasyfikacji DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) wyróżnia się trzy kategorie dysfunkcji seksualnych u kobiet: zaburzenia pożądania seksualnego i podniecenia, zaburzenia orgazmu oraz zaburzenia bólowe narządów płciowych/penetracji.¹¹ Aby spełnić kryteria diagnostyczne którejkolwiek z tych kategorii, objawy muszą utrzymywać się przez co najmniej 6 miesięcy, występować w 75-100% kontaktów seksualnych, wiązać się z osobistym cierpieniem i nie wynikać z innego stanu psychologicznego, medycznego, stosowanych leków lub substancji, ani nie być związane z problemami w relacji.¹²

W badaniu populacji kurdyjskich kobiet z zachodniej części Iranu wykryto dysfunkcję seksualną u 46,2% badanych. FSD przejawiała się jako problem z pożądaniem u 45,3% kobiet, problem z podnieceniem u 37,5%, problem z lubrykacją u 41,2%, problem z orgazmem u 42,0%, problem z satysfakcją u 44,5% i problem z bólem u 42,5%.¹³

W badaniu NHSLS niskie pożądanie seksualne zgłosiło 22% kobiet, problemy z podnieceniem 14%, a ból podczas stosunku 7%.¹⁴ Dyspareunia występowała u 15,5% kobiet posiadających partnerów, a problemy z lubrykacją doświadczało około 21% badanych.¹⁵

Rozpowszechnienie zaburzeń orgazmu u kobiet waha się znacznie w raportach epidemiologicznych, od 10% w Europie Północnej do 34% w Azji Południowo-Wschodniej.¹⁶ W prowadzonych badaniach częstość występowania zaburzeń orgazmu wynosiła od 21% do 28,5% i była związana z zaburzeniami podniecenia (tj. brakiem lubrykacji) u 65% respondentek.¹⁷

Dysfunkcje seksualne w różnych grupach wiekowych

Dysfunkcja seksualna może wystąpić w każdym wieku, jednak częstość jej występowania różni się w zależności od wieku.¹⁸ Szczyt występowania FSD przypada na kobiety w wieku 51-59 lat, czyli w okresie menopauzy, choć może ona dotykać kobiety w każdym wieku.¹⁹

W badaniu kurdyjskich kobiet częstość występowania FSD zwiększała się wraz z wiekiem, od 22% u kobiet w wieku 20 lat do 75,7% u kobiet w wieku 40-50 lat.²⁰ Badanie PRESIDE wykazało, że chociaż częstość występowania jakiegokolwiek typu dysfunkcji seksualnej była najwyższa u kobiet powyżej 65 roku życia, częstość występowania cierpienia z tego powodu była najniższa w tej grupie wiekowej, a najwyższa u kobiet w średnim wieku między 45 a 65 rokiem życia.²¹

Według innych badań, dysfunkcja seksualna występuje u 10% kobiet w wieku 18-44 lat, 15% kobiet w wieku 45-65 lat i 9% kobiet w wieku 65-85 lat.²² Co ciekawe, młodszy wiek był istotnym predyktorem bólu podczas stosunku, braku przyjemności i lęku związanego z wydajnością seksualną.²³

Czynniki ryzyka dysfunkcji seksualnej kobiet

Życie seksualne i reprodukcyjne kobiet jest silnie związane z dysfunkcją seksualną, a szereg czynników biologicznych, psychologicznych i społecznych odgrywa rolę w jej występowaniu.²⁴

Do czynników związanych ze zwiększonym ryzykiem FSD należą:²⁵

Zwiększający się wiek
Menopauza (w tym przedwczesna niewydolność jajników)
Okres po porodzie
Zabiegi chirurgiczne narządów płciowych
Atrofia narządów płciowych
Okaleczenie narządów płciowych
Wykorzystanie seksualne
Czynniki psychologiczne
Problemy w związku
Alkohol i zaburzenia związane z używaniem substancji
Palenie tytoniu
Otyłość

²⁶

W badaniu kurdyjskich kobiet pacjentki z FSD były znacznie częściej starsze niż 40 lat (OR: 2,23, 95% CI: 1,12-2,68), odbywały stosunki seksualne rzadziej niż 3 razy w tygodniu (OR: 1,85, 95% CI: 1,23-1,99), były w związku małżeńskim przez 10 lat lub dłużej (OR: 1,76, 95% CI: 1,04-1,97), miały 3 lub więcej dzieci (OR: 1,48, 95% CI: 0,97-1,24), miały mężów w wieku 40 lat lub starszych (OR: 2,11, 95% CI: 1,35-2,37) i były bezrobotne (OR: 1,34, 95% CI: 1,06-1,63). Poziom wykształcenia był odwrotnie skorelowany z ryzykiem FSD (OR: 1,54, 95% CI: 1,09-2,13).²⁷

Nie stwierdzono istotnych różnic w historii palenia tytoniu, miejscu zamieszkania i stosowanych metodach antykoncepcji.²⁸

Dysfunkcje seksualne związane ze schorzeniami medycznymi i psychicznymi

Stany medyczne i psychiatryczne związane z dysfunkcją seksualną kobiet obejmują:²⁹

Choroby układu sercowo-naczyniowego
Cukrzyca
Choroby neurologiczne (udar, stwardnienie rozsiane, uszkodzenie rdzenia kręgowego)
Nadciśnienie
Zespół genitourinarny menopauzy
Nowotwory piersi, jajnika, macicy i szyjki macicy
Przebyte operacje ginekologiczne
Przewlekła niewydolność nerek
Nietrzymanie moczu

³⁰

Dysfunkcja seksualna kobiet silnie koreluje ze złym stanem zdrowia psychicznego i negatywnymi uczuciami wobec partnera, a nie z poziomem hormonów we krwi.³¹ Najczęstszym schorzeniem współistniejącym z FSD jest depresja, co zostało ocenione w badaniu PRESIDE.³² Pacjentki z depresją powinny być oceniane pod kątem FSD, a pacjentki z FSD powinny być oceniane pod kątem depresji.³³

Choroba sercowo-naczyniowa (CVD) jest związana ze zwiększoną częstością występowania FSD. Podobnie jak zaburzenia erekcji u mężczyzn, dysfunkcja seksualna u kobiet jest związana z ciężkością CVD.³⁴ Dysfunkcja seksualna jest również powszechnym objawem u kobiet cierpiących na infekcje i schorzenia urologiczne, takie jak śródmiąższowe zapalenie pęcherza moczowego, nietrzymanie moczu, zaburzenia opróżniania pęcherza, choroby przenoszone drogą płciową i choroby zapalne miednicy.³⁵

Dysfunkcje seksualne w okresie ciąży i menopauzy

Częstość występowania FSD wśród kobiet w ciąży wynosi 50-80%, głównie w pierwszym i trzecim trymestrze.³⁶ Około 83% kobiet doświadcza problemów seksualnych w pierwszych 3 miesiącach po porodzie.³⁷

Dysfunkcja seksualna jest powszechna u starszych kobiet. Wiele kobiet doświadcza zmiany w funkcjonowaniu seksualnym w okresie poprzedzającym i następującym po menopauzie.³⁸ U około 52,4% kobiet po naturalnej menopauzie — szacunkowo 16 milionów kobiet w wieku 50 lat i starszych — występuje niskie pożądanie seksualne i objawy FSD.³⁹

Dysfunkcje seksualne a poziom nierówności płci

Metaregresja danych wykazała pozytywną korelację między częstością występowania dysfunkcji seksualnej kobiet a poziomem nierówności płci w danym kraju (indeks nierówności płci z Programu Rozwoju Narodów Zjednoczonych).⁴⁰ Chociaż wyniki tych badań nie mogą wykazać związku przyczynowego między dysfunkcją seksualną a nierównością płci, to podkreślają znaczenie badania wyników zdrowia seksualnego w kontekście poziomu nierówności płci w społeczeństwie.⁴¹

Poszukiwanie pomocy medycznej w przypadku dysfunkcji seksualnych

Dysfunkcja seksualna kobiet pozostaje niedostatecznie rozpoznana i niedostatecznie leczona.⁴² Mniej niż 10% tych problemów jest zwykle zgłaszanych lekarzowi lub innemu pracownikowi służby zdrowia.⁴³ Według badań Bermana i wsp., 40% kobiet nie szukało pomocy lekarza z powodu swoich trudności seksualnych, podczas gdy 54% zgłosiło, że chciałoby to zrobić.⁴⁴

Niski poziom bezpośrednich skarg na problemy seksualne wśród kobiet w zachodnim Iranie o kulturze kurdyjskiej prawdopodobnie odzwierciedla czynniki kulturowe, takie jak nieśmiałość i zakłopotanie. Ponadto brak świadomości lekarzy na temat FSD może prowadzić do niewystarczającego rozpoznania i leczenia tych problemów.⁴⁵

Fakt, że większość respondentów nie szuka profesjonalnej pomocy po zauważeniu problemów w życiu seksualnym, jest niepokojący.⁴⁶

Podsumowanie danych epidemiologicznych

Dysfunkcja seksualna kobiet to istotny problem zdrowia publicznego, który dotyka około 41% kobiet w wieku przedmenopauzalnym na całym świecie.⁴⁷ Chociaż szacunki dotyczące częstości występowania FSD znacznie się różnią, badania konsekwentnie wykazują, że jest to powszechny problem, który dotyka kobiety we wszystkich grupach wiekowych, kulturach i grupach społeczno-ekonomicznych.⁴⁸

Dane epidemiologiczne są niezbędne dla lepszego zrozumienia czynników ryzyka i opracowania skutecznych strategii profilaktyki i leczenia. Dotychczasowe badania wskazują, że FSD jest wieloczynnikowa i ma silne powiązania z czynnikami psychospołecznymi, medycznymi i demograficznymi.⁴⁹

Lepsze zrozumienie epidemiologii FSD jest niezbędne do planowania skutecznych strategii leczenia i profilaktyki. FSD musi być uznana za istotny problem zdrowia publicznego, wymagający dalszych badań, szczególnie w zakresie świadomości i kompetencji lekarzy w zarządzaniu FSD.⁵⁰

Częstość występowania różnych typów dysfunkcji seksualnych u kobiet według badań populacyjnych
Typ dysfunkcji seksualnej	Częstość występowania (%)	Źródło badania
Ogólna dysfunkcja seksualna	40-50%	Metaanaliza 2016, NHSLS
Zaburzenia pożądania	22-45,3%	NHSLS, badania populacji kurdyjskiej
Zaburzenia podniecenia	14-37,5%	NHSLS, badania populacji kurdyjskiej
Problemy z lubrykacją	21-41,2%	NHSLS, badania populacji kurdyjskiej
Zaburzenia orgazmu	10-42%	Badania populacji kurdyjskiej, dane europejskie
Dyspareunia/ból	7-42,5%	NHSLS, badania populacji kurdyjskiej
Waginizm	4-6%	Badania populacyjne
Dysfunkcje u kobiet w ciąży	50-80%	Badania populacyjne
Dysfunkcje po porodzie	83%	Badania populacyjne
Dysfunkcje u kobiet po menopauzie	52,4%	Badania populacyjne

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1
https://link.springer.com/article/10.1007/s00345-002-0272-5
Female sexual dysfunction (FSD) is a multifactorial condition that has anatomical, physiological, medical, psychological, and social components. […] Similar to erectile dysfunction in men, FSD is highly prevalent and often undertreated. […] Only a few studies dealing with epidemiology of female sexual dysfunction are available in the literature. […] However, research efforts in the field are increasing. […] This overview presents currently used classification systems, recently updated definitions, as well as prevalence data on the different entities of female sexual disorders.
#2 Epidemiology of FSD » Sexual Medicine » BUMC
https://www.bumc.bu.edu/sexualmedicine/physicianinformation/epidemiology-of-fsd/
The epidemiology of female sexual dysfunction is not well understood for many reasons. Unbiased prevalence estimates from population-based samples have been rare, and incidence estimates have been nonexistent. Most published prevalence estimates have been based on selected clinical or volunteer samples. […] Accurate estimates of prevalence and incidence are important in understanding the burden of female sexual dysfunction in the community and in identifying risk factors for prevention efforts. […] Most published studies of the prevalence of sexual dysfunctions in women were performed in clinic or other selected samples. […] The overall prevalence of dysfunction was reported by three studies, and ranged from 19% to 42%. […] The NHSLS found a high overall prevalence of FSD (43%) in US women ages 18-59.
#3 Overview of sexual dysfunction in females: Epidemiology, risk factors, and evaluation – UpToDate
https://www.uptodate.com/contents/overview-of-sexual-dysfunction-in-females-epidemiology-risk-factors-and-evaluation
Overview of sexual dysfunction in females: Epidemiology, risk factors, and evaluation […] Sexual problems are reported by approximately 40 percent of females worldwide, and approximately 12 percent (one in every eight females) have a sexual problem associated with personal or interpersonal distress. […] Female sexual dysfunction refers to a sexual problem associated with personal distress. It takes different forms, including lack of sexual desire, impaired arousal, inability to achieve orgasm, or pain with sexual activity. […] The epidemiology, risk factors, and evaluation of female sexual dysfunction will be reviewed here. […] The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and treatment of female orgasmic disorder are also discussed separately.
#4 Overview of sexual dysfunction in females: Epidemiology, risk factors, and evaluation – UpToDate
https://www.uptodate.com/contents/overview-of-sexual-dysfunction-in-women-epidemiology-risk-factors-and-evaluation
Overview of sexual dysfunction in females: Epidemiology, risk factors, and evaluation […] Sexual problems are reported by approximately 40 percent of females worldwide, and approximately 12 percent (one in every eight females) have a sexual problem associated with personal or interpersonal distress. […] Female sexual dysfunction refers to a sexual problem associated with personal distress. It takes different forms, including lack of sexual desire, impaired arousal, inability to achieve orgasm, or pain with sexual activity. […] The epidemiology, risk factors, and evaluation of female sexual dysfunction will be reviewed here. […] The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and treatment of female orgasmic disorder are also discussed separately.
#5 Predictors of female sexual dysfunction: a systematic review and qualitative analysis through gender inequality paradigms | BMC Women’s Health | Full Text
https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-018-0602-4
Female sexual dysfunction affects 41% of reproductive-age women worldwide, making it a highly prevalent medical issue. […] A 2016 systematic review and meta-analysis assessed the prevalence rate of female sexual dysfunction in 215,740 reproductive-age women worldwide and found the 41% of these women report some form of female sexual dysfunction. […] A meta-regression of the collected data showed a positive correlation between the prevalence of female sexual dysfunction and the level of gender inequality in a country (Gender Inequality Index from the United Nations Development Program). […] The results of these two large-scale studies cannot show causality between sexual dysfunction and gender inequality, but they do underline the importance of examining sexual health outcomes in terms of the level of gender inequality in a society.
#6 Prevalence of Female Sexual Dysfunction Among Premenopausal Women: A Systematic Review and Meta-Analysis of Observational Studies – PubMed
https://pubmed.ncbi.nlm.nih.gov/27871953/
Epidemiologic research in female sexual dysfunction (FSD) has gained momentum in recent years, particularly in clinical populations and in menopausal women. […] However, sexual dysfunction also affects premenopausal women in general populations. Previous literature reviews have been unable to quantify the burden of FSD in general populations. […] The prevalence of FSD in premenopausal women was estimated to be 40.9% (95% CI = 37.1-44.7, I2 = 99.0%). […] Prevalence estimates of FSD vary substantially. Nonetheless, results show that FSD is a significant public health problem that affects 41% of premenopausal women around the globe.
#7 Epidemiology of FSD » Sexual Medicine » BUMC
https://www.bumc.bu.edu/sexualmedicine/physicianinformation/epidemiology-of-fsd/
The epidemiology of female sexual dysfunction is not well understood for many reasons. Unbiased prevalence estimates from population-based samples have been rare, and incidence estimates have been nonexistent. Most published prevalence estimates have been based on selected clinical or volunteer samples. […] Accurate estimates of prevalence and incidence are important in understanding the burden of female sexual dysfunction in the community and in identifying risk factors for prevention efforts. […] Most published studies of the prevalence of sexual dysfunctions in women were performed in clinic or other selected samples. […] The overall prevalence of dysfunction was reported by three studies, and ranged from 19% to 42%. […] The NHSLS found a high overall prevalence of FSD (43%) in US women ages 18-59.
#8 Epidemiology of FSD » Sexual Medicine » BUMC
https://www.bumc.bu.edu/sexualmedicine/patientinformation-physicians/epidemiology-of-fsd/
Sexual dysfunction is more prevalent in women than men overall. Studies have found that about 40% of women and 30% of men have one or more sexual problems in the past year. Less than 10% of these problems are typically brought to the attention of a physician or other health care provider. […] The epidemiology of sexual dysfunction in women (female sexual dysfunction or FSD) is best understood on data from a population based study. The National Health and Social Life Survey found a high overall prevalence of FSD (43%) in US women ages 18-59. […] Low desire was reported by 22%, arousal problems by 14%, and sexual pain by 7%. […] The prevalence of dyspareunia among women with partners was 15.5%, and trouble lubricating was experienced by about 21%. […] In general sexual dysfunction (FSD) was more common among younger women; the one exception was trouble with lubrication.
#9 Epidemiology of FSD » Sexual Medicine » BUMC
https://www.bumc.bu.edu/sexualmedicine/physicianinformation/epidemiology-of-fsd/
Estimates of dysfunction from an older population (60 years) is provided by a probability sample of adults in Michigan. […] Studies were performed in middle-aged women. The overall prevalence of sexual dysfunction was estimated at 33% in the UK and 22% in Iceland. […] Population estimates of inhibited desire are 22% in the US and 16% in Iceland. […] In conclusion, female sexual dysfunction is common condition, with population estimates ranging from 22% to 43%. […] Little is known about risk factors for female sexual dysfunction or changes over the life span (natural history).
#10 Sexual dysfunction in women: Can we talk about it? | Cleveland Clinic Journal of Medicine
https://www.ccjm.org/content/84/5/367
Sexual dysfunction in women is common and often goes unreported and untreated. Its management is part of patient-centered primary care. Primary care providers are uniquely positioned to identify and assess sexual health concerns of their patients, provide reassurance regarding normal sexual function, and treat sexual dysfunction or refer as appropriate. […] The age-adjusted prevalence of sexual dysfunction in US women was reported at 44% in the Prevalence of Female Sexual Problems Associated With Distress and Determinants of Treatment Seeking (PRESIDE) study, but the prevalence of distress associated with sexual dysfunction was 12%. The most common type of sexual dysfunction reported by women was low sexual desire, a finding consistent with that of another large population-based study. […] While the prevalence of any type of sexual dysfunction was highest in women over age 65, the prevalence of distress was lowest in this age group and highest in midlife between the ages of 45 and 65. The diagnostic criteria require both a problem and distress over the problem.
#11 Sexual dysfunction in women: Can we talk about it? | Cleveland Clinic Journal of Medicine
https://www.ccjm.org/content/84/5/367
Sexual dysfunction negatively affects quality of life and emotional health, regardless of age. […] The World Health Organization defines sexual health as a state of physical, emotional, mental, and social well-being in relation to sexuality and not merely the absence of disease, dysfunction, or infirmity. […] The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published in 2013, defines three categories of sexual dysfunction in women: Female sexual interest and arousal disorder, Female sexual orgasmic disorder, and Genitopelvic pain/penetration disorder. […] To meet the diagnosis of any of these, symptoms must persist for at least 6 months, occur in 75% to 100% of sexual encounters, be accompanied by personal distress, and not be related to another psychological or medical condition, medication or substance use, or relationship distress.
#12 Sexual dysfunction in women: Can we talk about it? | Cleveland Clinic Journal of Medicine
https://www.ccjm.org/content/84/5/367
Sexual dysfunction negatively affects quality of life and emotional health, regardless of age. […] The World Health Organization defines sexual health as a state of physical, emotional, mental, and social well-being in relation to sexuality and not merely the absence of disease, dysfunction, or infirmity. […] The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published in 2013, defines three categories of sexual dysfunction in women: Female sexual interest and arousal disorder, Female sexual orgasmic disorder, and Genitopelvic pain/penetration disorder. […] To meet the diagnosis of any of these, symptoms must persist for at least 6 months, occur in 75% to 100% of sexual encounters, be accompanied by personal distress, and not be related to another psychological or medical condition, medication or substance use, or relationship distress.
#13 Female Sexual Dysfunction: Prevalence and Risk Factors
https://pmc.ncbi.nlm.nih.gov/articles/PMC3919309/
Background and Aim: Sexual dysfunction adversely affects quality of life, self esteem and interpersonal relationships and it may often be responsible for psychopathological disturbances. The purpose of this study was to explore the prevalence and associated risk factors for Female Sexual Dysfunction (FSD) in women with Kurdish culture from western Iran. […] Results: According to the findings, 185 (46.2%) women reported FSD. Prevalence of FSD increased with age, from 22% in women aged 20 years to 75.7% in women aged 40-50 years. FSD was detected as a desire problem in 45.3% of women, an arousal problem in 37.5%, a lubrication problem in 41.2%, an orgasm problem in 42.0%, a satisfaction problem in 44.5% and a pain problem in 42.5%. The educational level was inversely correlated with the risk of FSD (OR: 1.54 ,95% CI: 1.09-2.13). Patients with FSD were significantly more likely to be older than 40 years (OR: 2.23, 95% CI: 1.12-2.68), who had sexual intercourse fewer than 3 times a week (OR:1.85, 95% CI: 1.23-1.99), who had been married for 10 years or more (OR:1.76, 95% CI: 1.04-1.97), who had 3 children or more (OR: 1.48, 95% CI: 0.97-1.24), who had husbands aged 40 years or more (OR: 2.11, 95% CI: 1.35-2.37) and who were unemployed (OR: 1.34, 95% CI: 1.06-1.63). No significant differences were detected in smoking history, residences and contraception methods used (p0.05).
#14 Epidemiology of FSD » Sexual Medicine » BUMC
https://www.bumc.bu.edu/sexualmedicine/patientinformation-physicians/epidemiology-of-fsd/
Sexual dysfunction is more prevalent in women than men overall. Studies have found that about 40% of women and 30% of men have one or more sexual problems in the past year. Less than 10% of these problems are typically brought to the attention of a physician or other health care provider. […] The epidemiology of sexual dysfunction in women (female sexual dysfunction or FSD) is best understood on data from a population based study. The National Health and Social Life Survey found a high overall prevalence of FSD (43%) in US women ages 18-59. […] Low desire was reported by 22%, arousal problems by 14%, and sexual pain by 7%. […] The prevalence of dyspareunia among women with partners was 15.5%, and trouble lubricating was experienced by about 21%. […] In general sexual dysfunction (FSD) was more common among younger women; the one exception was trouble with lubrication.
#15 Epidemiology of FSD » Sexual Medicine » BUMC
https://www.bumc.bu.edu/sexualmedicine/patientinformation-physicians/epidemiology-of-fsd/
Sexual dysfunction is more prevalent in women than men overall. Studies have found that about 40% of women and 30% of men have one or more sexual problems in the past year. Less than 10% of these problems are typically brought to the attention of a physician or other health care provider. […] The epidemiology of sexual dysfunction in women (female sexual dysfunction or FSD) is best understood on data from a population based study. The National Health and Social Life Survey found a high overall prevalence of FSD (43%) in US women ages 18-59. […] Low desire was reported by 22%, arousal problems by 14%, and sexual pain by 7%. […] The prevalence of dyspareunia among women with partners was 15.5%, and trouble lubricating was experienced by about 21%. […] In general sexual dysfunction (FSD) was more common among younger women; the one exception was trouble with lubrication.
#16
https://www.archivesofmedicalscience.com/Prevalence-of-sexual-dysfunctions-and-associated-risk-factors-in-Poland,109330,0,2.html
Data available on the prevalence of sexual dysfunctions are limited. Those related to sexual interest and desire disorders in men and most aspects of female sexual dysfunction (FSD) receive particularly scarce attention. […] According to the DSM-5 classification of mental disorders, female sexual dysfunctions constitute the sexual interest/arousal disorder (FSIAD), genito-pelvic pain/penetration disorder (GPPPD) and female orgasmic disorder (FOD). […] The prevalence of orgasmic dysfunction in women varies considerably in epidemiologic reports, ranging from 10% in Northern Europe to 34% in Southeast Asia. […] In our study, the prevalence of FOD was between 21 and 28.5% and was associated with arousal disorder (i.e. lack of lubrication) in 65% of responders. […] The prevalence of dyspareunia and vaginismus in our sample population studied was 19.1% and 4%, respectively. […] The disturbing fact is that most of the respondents do not seek professional help after noting problems in their sex life.
#17
https://www.archivesofmedicalscience.com/Prevalence-of-sexual-dysfunctions-and-associated-risk-factors-in-Poland,109330,0,2.html
Data available on the prevalence of sexual dysfunctions are limited. Those related to sexual interest and desire disorders in men and most aspects of female sexual dysfunction (FSD) receive particularly scarce attention. […] According to the DSM-5 classification of mental disorders, female sexual dysfunctions constitute the sexual interest/arousal disorder (FSIAD), genito-pelvic pain/penetration disorder (GPPPD) and female orgasmic disorder (FOD). […] The prevalence of orgasmic dysfunction in women varies considerably in epidemiologic reports, ranging from 10% in Northern Europe to 34% in Southeast Asia. […] In our study, the prevalence of FOD was between 21 and 28.5% and was associated with arousal disorder (i.e. lack of lubrication) in 65% of responders. […] The prevalence of dyspareunia and vaginismus in our sample population studied was 19.1% and 4%, respectively. […] The disturbing fact is that most of the respondents do not seek professional help after noting problems in their sex life.
#18 Sexual Dysfunction in Women | 5-Minute Clinical Consult
https://www.unboundmedicine.com/5minute/view/5-Minute-Clinical-Consult/1688527/1.1/Sexual_Dysfunction_in_Women
Female sexual dysfunction (FSD) is a common multidisciplinary concern faced by ~43% of women in the United States. […] According to ACOG, 43% of women disclose sexual function concerns, and about 12% of women feel that it causes personal distress. […] Sexual dysfunction can occur at any age, but rates vary by age. […] 74% incidence in women with gynecologic cancers. […] 83% of women experience problems in first 3 months after childbirth. […] Sexual dysfunction prevalence varies by age, with the highest prevalence in women aged 45 to 65 years (15%). […] Prevalence in women aged 18 to 44 years is 10%, whereas prevalence in women aged 65 to 85 years is 9%.
#19 Female Sexual Dysfunction: Practice Essentials, Pathophysiology, Epidemiology
https://emedicine.medscape.com/article/2500107-overview
Female sexual problems are common, although estimated prevalence varies greatly depending on who is asked and how the question is framed. […] Past estimates of the incidence of FSD range from approximately 10% if distress is used as a criterion, to 75% of menopausal women, if symptoms alone are used as the criterion. The peak age group for female sexual dysfunction (FSD) consists of women aged 51-59 years, around the time of menopause; however, FSD can occur in women of all ages. […] Thus, incidence and prevalence data based on this definition are developing.
#20 Female Sexual Dysfunction: Prevalence and Risk Factors
https://pmc.ncbi.nlm.nih.gov/articles/PMC3919309/
Background and Aim: Sexual dysfunction adversely affects quality of life, self esteem and interpersonal relationships and it may often be responsible for psychopathological disturbances. The purpose of this study was to explore the prevalence and associated risk factors for Female Sexual Dysfunction (FSD) in women with Kurdish culture from western Iran. […] Results: According to the findings, 185 (46.2%) women reported FSD. Prevalence of FSD increased with age, from 22% in women aged 20 years to 75.7% in women aged 40-50 years. FSD was detected as a desire problem in 45.3% of women, an arousal problem in 37.5%, a lubrication problem in 41.2%, an orgasm problem in 42.0%, a satisfaction problem in 44.5% and a pain problem in 42.5%. The educational level was inversely correlated with the risk of FSD (OR: 1.54 ,95% CI: 1.09-2.13). Patients with FSD were significantly more likely to be older than 40 years (OR: 2.23, 95% CI: 1.12-2.68), who had sexual intercourse fewer than 3 times a week (OR:1.85, 95% CI: 1.23-1.99), who had been married for 10 years or more (OR:1.76, 95% CI: 1.04-1.97), who had 3 children or more (OR: 1.48, 95% CI: 0.97-1.24), who had husbands aged 40 years or more (OR: 2.11, 95% CI: 1.35-2.37) and who were unemployed (OR: 1.34, 95% CI: 1.06-1.63). No significant differences were detected in smoking history, residences and contraception methods used (p0.05).
#21 Sexual dysfunction in women: Can we talk about it? | Cleveland Clinic Journal of Medicine
https://www.ccjm.org/content/84/5/367
Sexual dysfunction in women is common and often goes unreported and untreated. Its management is part of patient-centered primary care. Primary care providers are uniquely positioned to identify and assess sexual health concerns of their patients, provide reassurance regarding normal sexual function, and treat sexual dysfunction or refer as appropriate. […] The age-adjusted prevalence of sexual dysfunction in US women was reported at 44% in the Prevalence of Female Sexual Problems Associated With Distress and Determinants of Treatment Seeking (PRESIDE) study, but the prevalence of distress associated with sexual dysfunction was 12%. The most common type of sexual dysfunction reported by women was low sexual desire, a finding consistent with that of another large population-based study. […] While the prevalence of any type of sexual dysfunction was highest in women over age 65, the prevalence of distress was lowest in this age group and highest in midlife between the ages of 45 and 65. The diagnostic criteria require both a problem and distress over the problem.
#22 Sexual Dysfunction in Women | 5-Minute Clinical Consult
https://www.unboundmedicine.com/5minute/view/5-Minute-Clinical-Consult/1688527/1.1/Sexual_Dysfunction_in_Women
Female sexual dysfunction (FSD) is a common multidisciplinary concern faced by ~43% of women in the United States. […] According to ACOG, 43% of women disclose sexual function concerns, and about 12% of women feel that it causes personal distress. […] Sexual dysfunction can occur at any age, but rates vary by age. […] 74% incidence in women with gynecologic cancers. […] 83% of women experience problems in first 3 months after childbirth. […] Sexual dysfunction prevalence varies by age, with the highest prevalence in women aged 45 to 65 years (15%). […] Prevalence in women aged 18 to 44 years is 10%, whereas prevalence in women aged 65 to 85 years is 9%.
#23 Epidemiology of FSD » Sexual Medicine » BUMC
https://www.bumc.bu.edu/sexualmedicine/patientinformation-physicians/epidemiology-of-fsd/
Younger age was a significant predictor for pain during sex, lack of pleasure, and anxiety about performance. […] Women with a lower level of education were also more likely to experience pain during sex. […] Arousal disorder (FSAD) was higher among women with a urinary tract symptom, emotional problems or stress, infrequent thoughts about sex, and a history of being sexually touched before puberty and sexually forced by a man ever. […] Sexual pain was increased in women with a urinary tract symptom, and emotional problems or stress, and among those reporting poor to fair health, and a 20% decrease in household income. […] Low physical and emotional satisfaction and low general happiness were significant correlates of all three sexual dysfunction categories: low desire, arousal disorder and sexual pain.
#24 Predictors of female sexual dysfunction: a systematic review and qualitative analysis through gender inequality paradigms | BMC Women’s Health | Full Text
https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-018-0602-4
The sexual and reproductive lives of women are highly impacted by female sexual dysfunction, and a number of biological, psychological and social factors play a role in the prevalence of sexual dysfunction. […] Healthcare professionals who work with women should be aware of the many risk factors for reproductive-age women. […] Future prevention strategies should aim to address modifiable factors, e.g. physical activity and access to sex education; international efforts in empowering women should continue.
#25 Female Sexual Dysfunction | Doctor
https://patient.info/doctor/female-sexual-dysfunction-pro
The factors associated with an increased risk of FSD include increasing age, menopause (including premature ovarian failure), the postpartum period, genital surgery, genital atrophy, genital mutilation, sexual abuse, psychological factors, relationship problems, alcohol, substance use disorders, smoking, and obesity. […] Medical and psychiatric conditions that are associated with female sexual dysfunction include cardiovascular disease, diabetes mellitus, neurologic disease (stroke, multiple sclerosis, spinal cord injury), hypertension, genitourinary syndrome of menopause, breast, ovarian, uterine, and cervical cancer, history of gynaecological surgery, chronic renal failure, and urinary incontinence.
#26 Female Sexual Dysfunction | Doctor
https://patient.info/doctor/female-sexual-dysfunction-pro
The factors associated with an increased risk of FSD include increasing age, menopause (including premature ovarian failure), the postpartum period, genital surgery, genital atrophy, genital mutilation, sexual abuse, psychological factors, relationship problems, alcohol, substance use disorders, smoking, and obesity. […] Medical and psychiatric conditions that are associated with female sexual dysfunction include cardiovascular disease, diabetes mellitus, neurologic disease (stroke, multiple sclerosis, spinal cord injury), hypertension, genitourinary syndrome of menopause, breast, ovarian, uterine, and cervical cancer, history of gynaecological surgery, chronic renal failure, and urinary incontinence.
#27 Female Sexual Dysfunction: Prevalence and Risk Factors
https://pmc.ncbi.nlm.nih.gov/articles/PMC3919309/
Background and Aim: Sexual dysfunction adversely affects quality of life, self esteem and interpersonal relationships and it may often be responsible for psychopathological disturbances. The purpose of this study was to explore the prevalence and associated risk factors for Female Sexual Dysfunction (FSD) in women with Kurdish culture from western Iran. […] Results: According to the findings, 185 (46.2%) women reported FSD. Prevalence of FSD increased with age, from 22% in women aged 20 years to 75.7% in women aged 40-50 years. FSD was detected as a desire problem in 45.3% of women, an arousal problem in 37.5%, a lubrication problem in 41.2%, an orgasm problem in 42.0%, a satisfaction problem in 44.5% and a pain problem in 42.5%. The educational level was inversely correlated with the risk of FSD (OR: 1.54 ,95% CI: 1.09-2.13). Patients with FSD were significantly more likely to be older than 40 years (OR: 2.23, 95% CI: 1.12-2.68), who had sexual intercourse fewer than 3 times a week (OR:1.85, 95% CI: 1.23-1.99), who had been married for 10 years or more (OR:1.76, 95% CI: 1.04-1.97), who had 3 children or more (OR: 1.48, 95% CI: 0.97-1.24), who had husbands aged 40 years or more (OR: 2.11, 95% CI: 1.35-2.37) and who were unemployed (OR: 1.34, 95% CI: 1.06-1.63). No significant differences were detected in smoking history, residences and contraception methods used (p0.05).
#28 Female Sexual Dysfunction: Prevalence and Risk Factors
https://pmc.ncbi.nlm.nih.gov/articles/PMC3919309/
Background and Aim: Sexual dysfunction adversely affects quality of life, self esteem and interpersonal relationships and it may often be responsible for psychopathological disturbances. The purpose of this study was to explore the prevalence and associated risk factors for Female Sexual Dysfunction (FSD) in women with Kurdish culture from western Iran. […] Results: According to the findings, 185 (46.2%) women reported FSD. Prevalence of FSD increased with age, from 22% in women aged 20 years to 75.7% in women aged 40-50 years. FSD was detected as a desire problem in 45.3% of women, an arousal problem in 37.5%, a lubrication problem in 41.2%, an orgasm problem in 42.0%, a satisfaction problem in 44.5% and a pain problem in 42.5%. The educational level was inversely correlated with the risk of FSD (OR: 1.54 ,95% CI: 1.09-2.13). Patients with FSD were significantly more likely to be older than 40 years (OR: 2.23, 95% CI: 1.12-2.68), who had sexual intercourse fewer than 3 times a week (OR:1.85, 95% CI: 1.23-1.99), who had been married for 10 years or more (OR:1.76, 95% CI: 1.04-1.97), who had 3 children or more (OR: 1.48, 95% CI: 0.97-1.24), who had husbands aged 40 years or more (OR: 2.11, 95% CI: 1.35-2.37) and who were unemployed (OR: 1.34, 95% CI: 1.06-1.63). No significant differences were detected in smoking history, residences and contraception methods used (p0.05).
#29 Female Sexual Dysfunction | Doctor
https://patient.info/doctor/female-sexual-dysfunction-pro
The factors associated with an increased risk of FSD include increasing age, menopause (including premature ovarian failure), the postpartum period, genital surgery, genital atrophy, genital mutilation, sexual abuse, psychological factors, relationship problems, alcohol, substance use disorders, smoking, and obesity. […] Medical and psychiatric conditions that are associated with female sexual dysfunction include cardiovascular disease, diabetes mellitus, neurologic disease (stroke, multiple sclerosis, spinal cord injury), hypertension, genitourinary syndrome of menopause, breast, ovarian, uterine, and cervical cancer, history of gynaecological surgery, chronic renal failure, and urinary incontinence.
#30 Female Sexual Dysfunction | Doctor
https://patient.info/doctor/female-sexual-dysfunction-pro
The factors associated with an increased risk of FSD include increasing age, menopause (including premature ovarian failure), the postpartum period, genital surgery, genital atrophy, genital mutilation, sexual abuse, psychological factors, relationship problems, alcohol, substance use disorders, smoking, and obesity. […] Medical and psychiatric conditions that are associated with female sexual dysfunction include cardiovascular disease, diabetes mellitus, neurologic disease (stroke, multiple sclerosis, spinal cord injury), hypertension, genitourinary syndrome of menopause, breast, ovarian, uterine, and cervical cancer, history of gynaecological surgery, chronic renal failure, and urinary incontinence.
#31 Sexual dysfunction in women – Symptoms, diagnosis and treatment | BMJ Best Practice
https://bestpractice.bmj.com/topics/en-gb/352
Sexual dysfunction in women of all sexual orientations correlates most strongly with poor mental health and with negative feelings for the partner(s), rather than with any serum hormone (or hormone metabolite) levels. […] Poor mental health, stress, and low levels of emotional intimacy between the partners correlate closely with dysfunction, whereas serum levels of sex hormones do not. […] There is only limited research on persistent genital arousal disorder/genito-pelvic dysesthesia (PGAD/GPD) and its pathophysiology and treatment are not well understood. […] The International Society for the Study of Women’s Sexual Health process of care for the identification of sexual concerns and problems in women.
#32 Understanding and Treating Female Sexual Dysfunction: An Update on Current Literature
https://evolvemeded.com/specialty/womens-health/understanding-and-treating-female-sexual-dysfunction-an-update-on-current-literature/27235/
Extrapolated, this means nearly 50% of female patients will have sexual function concerns. […] There are a number of modifiable factors impacting sexual functioning that should be addressed prior to a sexual disorder diagnosis. […] The most common comorbid condition with FSD is depression, which was evaluated in the PRESIDE study. […] The take-home message from this 2012 meta-analysis is that patients with depression should be assessed for FSD, and patients with FSD should be assessed for depression. […] The current standard of care for patients suffering with HSDD fall into several different categories, including nonpharmacological approaches and prescription medications. […] Flibanserin is now an FDA-approved option for HSDD in premenopausal women. […] The FDA evaluates pharmacologic treatments based on safety and efficacy and requires sponsors of investigational drugs to use validated measures of sexual function and distress in clinical trials. […] Flibanserin is currently the only FDA approved treatment for HSDD in premenopausal women.
#33 Understanding and Treating Female Sexual Dysfunction: An Update on Current Literature
https://evolvemeded.com/specialty/womens-health/understanding-and-treating-female-sexual-dysfunction-an-update-on-current-literature/27235/
Extrapolated, this means nearly 50% of female patients will have sexual function concerns. […] There are a number of modifiable factors impacting sexual functioning that should be addressed prior to a sexual disorder diagnosis. […] The most common comorbid condition with FSD is depression, which was evaluated in the PRESIDE study. […] The take-home message from this 2012 meta-analysis is that patients with depression should be assessed for FSD, and patients with FSD should be assessed for depression. […] The current standard of care for patients suffering with HSDD fall into several different categories, including nonpharmacological approaches and prescription medications. […] Flibanserin is now an FDA-approved option for HSDD in premenopausal women. […] The FDA evaluates pharmacologic treatments based on safety and efficacy and requires sponsors of investigational drugs to use validated measures of sexual function and distress in clinical trials. […] Flibanserin is currently the only FDA approved treatment for HSDD in premenopausal women.
#34 Female Sexual Dysfunction | Doctor
https://patient.info/doctor/female-sexual-dysfunction-pro
How common is female sexual dysfunction? (Epidemiology) […] 45% of midlife women have sexual problems, and 15% have a sexual problem that causes significant personal distress. Female sexual dysfunction remains under-recognised and undertreated. […] Sexual dysfunction is highly prevalent in older women. Many women experience a change in their sexual function during the years immediately before and after menopause. […] The prevalence of FSD among pregnant women is reported in 50-80% of women, mainly in the first and third trimesters. […] Cardiovascular disease (CVD) is associated with an increased prevalence of FSD. […] Sexual dysfunction, like erectile dysfunction in men, is related to the severity of CVD. […] Sexual difficulties in chronic pain are frequent and wide-ranging. Prevalence rates of sexual difficulties consistently range from 50-78%.
#35 Female Sexual Dysfunction: From Causality to Cure
https://www-staging.uspharmacist.com/article/female-sexual-dysfunction-from-causality-to-cure
Female sexual dysfunction (FSD) is a highly prevalent disorder affecting women’s quality of life across the lifespan and around the world. In the United States, according to results of the National Health and Social Life Survey, nearly 43% of women younger than age 60 experience some type of sexual dysfunction. […] Approximately 52.4% of naturally menopausal women–an estimated 16 million women aged 50 and older–are likely to be affected by low sexual desire and symptoms of FSD. […] Sexual dysfunction is a common manifestation in women suffering from urologic infections and conditions such as interstitial cystitis, urinary incontinence, disorders of bladder-emptying, sexually transmitted diseases, and pelvic inflammatory disease. […] Sexual dysfunction affects millions of women in the U.S. and worldwide.
#36 Female Sexual Dysfunction | Doctor
https://patient.info/doctor/female-sexual-dysfunction-pro
How common is female sexual dysfunction? (Epidemiology) […] 45% of midlife women have sexual problems, and 15% have a sexual problem that causes significant personal distress. Female sexual dysfunction remains under-recognised and undertreated. […] Sexual dysfunction is highly prevalent in older women. Many women experience a change in their sexual function during the years immediately before and after menopause. […] The prevalence of FSD among pregnant women is reported in 50-80% of women, mainly in the first and third trimesters. […] Cardiovascular disease (CVD) is associated with an increased prevalence of FSD. […] Sexual dysfunction, like erectile dysfunction in men, is related to the severity of CVD. […] Sexual difficulties in chronic pain are frequent and wide-ranging. Prevalence rates of sexual difficulties consistently range from 50-78%.
#37 Sexual Dysfunction in Women | 5-Minute Clinical Consult
https://www.unboundmedicine.com/5minute/view/5-Minute-Clinical-Consult/1688527/1.1/Sexual_Dysfunction_in_Women
Female sexual dysfunction (FSD) is a common multidisciplinary concern faced by ~43% of women in the United States. […] According to ACOG, 43% of women disclose sexual function concerns, and about 12% of women feel that it causes personal distress. […] Sexual dysfunction can occur at any age, but rates vary by age. […] 74% incidence in women with gynecologic cancers. […] 83% of women experience problems in first 3 months after childbirth. […] Sexual dysfunction prevalence varies by age, with the highest prevalence in women aged 45 to 65 years (15%). […] Prevalence in women aged 18 to 44 years is 10%, whereas prevalence in women aged 65 to 85 years is 9%.
#38 Female Sexual Dysfunction | Doctor
https://patient.info/doctor/female-sexual-dysfunction-pro
How common is female sexual dysfunction? (Epidemiology) […] 45% of midlife women have sexual problems, and 15% have a sexual problem that causes significant personal distress. Female sexual dysfunction remains under-recognised and undertreated. […] Sexual dysfunction is highly prevalent in older women. Many women experience a change in their sexual function during the years immediately before and after menopause. […] The prevalence of FSD among pregnant women is reported in 50-80% of women, mainly in the first and third trimesters. […] Cardiovascular disease (CVD) is associated with an increased prevalence of FSD. […] Sexual dysfunction, like erectile dysfunction in men, is related to the severity of CVD. […] Sexual difficulties in chronic pain are frequent and wide-ranging. Prevalence rates of sexual difficulties consistently range from 50-78%.
#39 Female Sexual Dysfunction: From Causality to Cure
https://www-staging.uspharmacist.com/article/female-sexual-dysfunction-from-causality-to-cure
Female sexual dysfunction (FSD) is a highly prevalent disorder affecting women’s quality of life across the lifespan and around the world. In the United States, according to results of the National Health and Social Life Survey, nearly 43% of women younger than age 60 experience some type of sexual dysfunction. […] Approximately 52.4% of naturally menopausal women–an estimated 16 million women aged 50 and older–are likely to be affected by low sexual desire and symptoms of FSD. […] Sexual dysfunction is a common manifestation in women suffering from urologic infections and conditions such as interstitial cystitis, urinary incontinence, disorders of bladder-emptying, sexually transmitted diseases, and pelvic inflammatory disease. […] Sexual dysfunction affects millions of women in the U.S. and worldwide.
#40 Predictors of female sexual dysfunction: a systematic review and qualitative analysis through gender inequality paradigms | BMC Women’s Health | Full Text
https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-018-0602-4
Female sexual dysfunction affects 41% of reproductive-age women worldwide, making it a highly prevalent medical issue. […] A 2016 systematic review and meta-analysis assessed the prevalence rate of female sexual dysfunction in 215,740 reproductive-age women worldwide and found the 41% of these women report some form of female sexual dysfunction. […] A meta-regression of the collected data showed a positive correlation between the prevalence of female sexual dysfunction and the level of gender inequality in a country (Gender Inequality Index from the United Nations Development Program). […] The results of these two large-scale studies cannot show causality between sexual dysfunction and gender inequality, but they do underline the importance of examining sexual health outcomes in terms of the level of gender inequality in a society.
#41 Predictors of female sexual dysfunction: a systematic review and qualitative analysis through gender inequality paradigms | BMC Women’s Health | Full Text
https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-018-0602-4
Female sexual dysfunction affects 41% of reproductive-age women worldwide, making it a highly prevalent medical issue. […] A 2016 systematic review and meta-analysis assessed the prevalence rate of female sexual dysfunction in 215,740 reproductive-age women worldwide and found the 41% of these women report some form of female sexual dysfunction. […] A meta-regression of the collected data showed a positive correlation between the prevalence of female sexual dysfunction and the level of gender inequality in a country (Gender Inequality Index from the United Nations Development Program). […] The results of these two large-scale studies cannot show causality between sexual dysfunction and gender inequality, but they do underline the importance of examining sexual health outcomes in terms of the level of gender inequality in a society.
#42 Female Sexual Dysfunction | Doctor
https://patient.info/doctor/female-sexual-dysfunction-pro
How common is female sexual dysfunction? (Epidemiology) […] 45% of midlife women have sexual problems, and 15% have a sexual problem that causes significant personal distress. Female sexual dysfunction remains under-recognised and undertreated. […] Sexual dysfunction is highly prevalent in older women. Many women experience a change in their sexual function during the years immediately before and after menopause. […] The prevalence of FSD among pregnant women is reported in 50-80% of women, mainly in the first and third trimesters. […] Cardiovascular disease (CVD) is associated with an increased prevalence of FSD. […] Sexual dysfunction, like erectile dysfunction in men, is related to the severity of CVD. […] Sexual difficulties in chronic pain are frequent and wide-ranging. Prevalence rates of sexual difficulties consistently range from 50-78%.
#43 Epidemiology of FSD » Sexual Medicine » BUMC
https://www.bumc.bu.edu/sexualmedicine/patientinformation-physicians/epidemiology-of-fsd/
Sexual dysfunction is more prevalent in women than men overall. Studies have found that about 40% of women and 30% of men have one or more sexual problems in the past year. Less than 10% of these problems are typically brought to the attention of a physician or other health care provider. […] The epidemiology of sexual dysfunction in women (female sexual dysfunction or FSD) is best understood on data from a population based study. The National Health and Social Life Survey found a high overall prevalence of FSD (43%) in US women ages 18-59. […] Low desire was reported by 22%, arousal problems by 14%, and sexual pain by 7%. […] The prevalence of dyspareunia among women with partners was 15.5%, and trouble lubricating was experienced by about 21%. […] In general sexual dysfunction (FSD) was more common among younger women; the one exception was trouble with lubrication.
#44 Female Sexual Dysfunction: Prevalence and Risk Factors
https://pmc.ncbi.nlm.nih.gov/articles/PMC3919309/
FSD has a major impact on quality of life and interpersonal relationships. For many women, it is physically disconcerting, emotionally distressing and socially disruptive. The strength of our study was the use of the Iranian version of the FSFI which was used to investigate FSD; a version which was not used in past Iranian FSD research. The major advantage of our study was the fact that, in contrast to mailed surveys, co-morbidities were assessed and verified by interviewers. […] Large differences have been found in the prevalences of FSD between countries. They may reflect medical and psychological factors, particularly in the settings of possible socioeconomic, cultural and racial differences, the clinical definition used for each dysfunction, type of trial performed (self-applicable questionnaire, mailed questionnaire, interview by phone, personal interview), interrelation with their partners, educational levels and the characteristics of samples (general population vs sexuality clinics) which were studied. Our data were also consistent with the results of Berman et al., who reported that 40% of women did not seek help from a physician for their sexual difficulties, whereas 54% reported that they would like to do so. The low rate of direct complaints on sexual problems among women in western Iran with Kurdish culture probably reflects cultural factors such as shyness and embarrassment. In addition, lack of awareness on FSD of physicians can lead to inadequate identification and management of these problems.
#45 Female Sexual Dysfunction: Prevalence and Risk Factors
https://pmc.ncbi.nlm.nih.gov/articles/PMC3919309/
FSD has a major impact on quality of life and interpersonal relationships. For many women, it is physically disconcerting, emotionally distressing and socially disruptive. The strength of our study was the use of the Iranian version of the FSFI which was used to investigate FSD; a version which was not used in past Iranian FSD research. The major advantage of our study was the fact that, in contrast to mailed surveys, co-morbidities were assessed and verified by interviewers. […] Large differences have been found in the prevalences of FSD between countries. They may reflect medical and psychological factors, particularly in the settings of possible socioeconomic, cultural and racial differences, the clinical definition used for each dysfunction, type of trial performed (self-applicable questionnaire, mailed questionnaire, interview by phone, personal interview), interrelation with their partners, educational levels and the characteristics of samples (general population vs sexuality clinics) which were studied. Our data were also consistent with the results of Berman et al., who reported that 40% of women did not seek help from a physician for their sexual difficulties, whereas 54% reported that they would like to do so. The low rate of direct complaints on sexual problems among women in western Iran with Kurdish culture probably reflects cultural factors such as shyness and embarrassment. In addition, lack of awareness on FSD of physicians can lead to inadequate identification and management of these problems.
#46
https://www.archivesofmedicalscience.com/Prevalence-of-sexual-dysfunctions-and-associated-risk-factors-in-Poland,109330,0,2.html
Data available on the prevalence of sexual dysfunctions are limited. Those related to sexual interest and desire disorders in men and most aspects of female sexual dysfunction (FSD) receive particularly scarce attention. […] According to the DSM-5 classification of mental disorders, female sexual dysfunctions constitute the sexual interest/arousal disorder (FSIAD), genito-pelvic pain/penetration disorder (GPPPD) and female orgasmic disorder (FOD). […] The prevalence of orgasmic dysfunction in women varies considerably in epidemiologic reports, ranging from 10% in Northern Europe to 34% in Southeast Asia. […] In our study, the prevalence of FOD was between 21 and 28.5% and was associated with arousal disorder (i.e. lack of lubrication) in 65% of responders. […] The prevalence of dyspareunia and vaginismus in our sample population studied was 19.1% and 4%, respectively. […] The disturbing fact is that most of the respondents do not seek professional help after noting problems in their sex life.
#47 Prevalence of Female Sexual Dysfunction Among Premenopausal Women: A Systematic Review and Meta-Analysis of Observational Studies – PubMed
https://pubmed.ncbi.nlm.nih.gov/27871953/
Epidemiologic research in female sexual dysfunction (FSD) has gained momentum in recent years, particularly in clinical populations and in menopausal women. […] However, sexual dysfunction also affects premenopausal women in general populations. Previous literature reviews have been unable to quantify the burden of FSD in general populations. […] The prevalence of FSD in premenopausal women was estimated to be 40.9% (95% CI = 37.1-44.7, I2 = 99.0%). […] Prevalence estimates of FSD vary substantially. Nonetheless, results show that FSD is a significant public health problem that affects 41% of premenopausal women around the globe.
#48 Female Sexual Dysfunction in Association with Sexual History, Sexual Abuse and Satisfaction: A Cross-Sectional Study in Hungary
https://www.mdpi.com/2077-0383/12/3/1112
Female sexual dysfunction (FSD) is a heterogeneous group of multi-causal and multi-dimensional medical disorders that adversely affect physical health and emotional well-being. FSD is a common condition in women of all ages and has a negative impact not only on their quality of life but also on the sexual function and quality of life of their partners. […] In various studies, the prevalence of FSD among sexually active women is between 30 and 50%. According to the consensus of the 4th International Consultation on Sexual Medicine (ICSM) in 2015, the prevalence of at least one sexual dysfunction among women, regardless of their age, is approximately 40â50%. The results from a global study of 27,500 people (about half of whom were women aged 40â80 years) showed that a large proportion of women experienced multiple sexual dysfunctions: 17% in Northern Europe and 34% in Southeast Asia. In Slovenia, the prevalence of women with at least one sexual dysfunction is 31%.
#49 Female Sexual Dysfunction: Prevalence and Risk Factors
https://pmc.ncbi.nlm.nih.gov/articles/PMC3919309/
This study provides estimates of the prevalence of FSD in Iranian Kurd women using the Iranian version of the FSFI. These results suggest that lifestyle changes may play a role in causation of FSD. Better understanding of the epidemiology of FSD is vital, to plan effective treatment and prevention strategies. FSD needs to be recognized as a significant public health problem in western Iran, with an urgent need for further research, particularly studies into awareness and competency of physicians in the management of FSD.
#50 Female Sexual Dysfunction: Prevalence and Risk Factors
https://pmc.ncbi.nlm.nih.gov/articles/PMC3919309/
This study provides estimates of the prevalence of FSD in Iranian Kurd women using the Iranian version of the FSFI. These results suggest that lifestyle changes may play a role in causation of FSD. Better understanding of the epidemiology of FSD is vital, to plan effective treatment and prevention strategies. FSD needs to be recognized as a significant public health problem in western Iran, with an urgent need for further research, particularly studies into awareness and competency of physicians in the management of FSD.